Carregant...

Chimeric antigen receptor T cells for mature B-cell lymphoma and Burkitt lymphoma

Chimeric antigen receptor (CAR) T-cell therapy has changed the landscape of immunotherapy for B-cell malignancies, including mature B-cell lymphomas. Although two CD19 CAR T-cell products have been commercially approved to treat relapsed/refractory B-cell lymphomas, outcomes in these patients remain...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Hematology Am Soc Hematol Educ Program
Autors principals: Hsieh, Emily M., Rouce, Rayne H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2020
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7727550/
https://ncbi.nlm.nih.gov/pubmed/33275669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/hematology.2020000133
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!